evipedia.ai
← Back

Oroxylum indicum for Health & Longevity

Evidence Review created on 09/24/2026 using AI4L / Opus 5.5

Also known as: Indian Trumpet Tree, Indian Trumpet Flower, Broken Bones Tree, Scythe Tree, Midnight Horror, Tree of Damocles, Sonapatha, Shyonaka, Syonaka, Tetu, Beko, Pheka, Mu Hu Die, Semen Oroxyli, Sabroxy, Bignonia indica

Motivation

Oroxylum indicum, the Indian trumpet tree (Sonapatha, Shyonaka), is a fast-growing Asian tree whose bark, root, and seeds have long served as herbal remedies. Its bark is rich in plant pigments called flavones, which in laboratory work protect nerve cells and slow the clearance of dopamine, a brain messenger linked to focus. A standardized bark extract is now sold as a supplement for memory and focus.

The tree is one of the ten roots of Dashamoola, a classic Ayurvedic formula still in wide use, and its seeds appear in traditional Chinese medicine. Interest from people pursuing healthy aging rests on one placebo-controlled trial in older adults with memory complaints, in which the extract improved some memory tasks but not overall thinking scores, together with a large body of animal and cell research on metabolic health.

This review examines the human and laboratory evidence on its benefits, its risks and drug interactions, the doses studied, and the independence of the research base, with a focus on memory and metabolic health as parts of long-term healthy aging.

Benefits - Risks - Protocol - Conclusion

The following items give a high-level overview of Oroxylum indicum, its signature flavone oroxylin A, and the only human efficacy trial of its standardized extract.

No content from the priority experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, Lifespan.io) discussing Oroxylum indicum, Sabroxy, or oroxylin A was found; the plant has not been covered on these platforms, although Life Extension’s own site search could not be loaded.

Grokipedia

Oroxylum indicum

A machine-generated encyclopedia entry covering the tree’s taxonomy, distribution, Ayurvedic and Southeast Asian uses, and principal flavonoids; useful as botanical background rather than clinical evidence.

Examine

Oroxylum indicum

A brief evidence summary describing the plant as a flavonoid-rich traditional medicine most often used for blood sugar, with a research feed tracking new studies on the plant.

ConsumerLab

No ConsumerLab article on Oroxylum indicum (or its Sabroxy extract) exists; ConsumerLab has not tested or reviewed products containing this herb.

Systematic Reviews

The following systematic reviews and meta-analyses cover Oroxylum indicum, its standardized extract, and its principal flavone baicalein.

On the risk side, only the network meta-analysis (a method comparing many treatments across trials) above addresses adverse effects, and only as adverse-event rates pooled across botanicals; no systematic review or meta-analysis addresses herb–drug interactions, the other principal risk, so that part of the trade-off is unrepresented in this section.

Mechanism of Action

Oroxylum indicum bark extracts act mainly through three flavones (oroxylin A, baicalein, and chrysin), while the seeds add glycosides (sugar-bound flavones) such as oroxin A. Proposed mechanisms come mostly from cell and animal work:

  • Brain signaling: oroxylin A blocks dopamine reuptake in cell studies and binds the benzodiazepine site (where calming drugs such as diazepam act) of the GABA-A receptor (gamma-aminobutyric acid type A receptor, the brain’s main calming receptor) as a blocker, an alerting profile in rodents (Yoon et al., 2013; Huen et al., 2003).
  • Nerve-cell support: oroxylin A raises BDNF (brain-derived neurotrophic factor, a protein that supports nerve-cell growth) in the mouse hippocampus (memory center) (Kim et al., 2014).
  • Inflammation and metabolism: baicalein and chrysin suppress NF-κB (nuclear factor kappa B, a master switch of inflammation) (Sun et al., 2021); oroxin A partially activates PPAR-γ (peroxisome proliferator-activated receptor gamma, a regulator of insulin sensitivity) and inhibits α-glucosidase (a gut enzyme that releases glucose from starch) (Sun et al., 2018).

The competing view centers on exposure. The flavones are rapidly conjugated by UGT enzymes (UDP-glucuronosyltransferases, which tag compounds for excretion); free chrysin peaked at only 3–16 ng/mL after 400 mg in volunteers (Walle et al., 2001). Isolated baicalein has a terminal half-life of about 11–15 hours and accumulates with repeat dosing (Li et al., 2021). The flavones reach rodent brain (Fong et al., 2017), act on many targets, and baicalein inhibits CYP3A4 (the liver enzyme that clears about half of prescription drugs) (Meng et al., 2021).

Historical Context & Evolution

Oroxylum indicum has been used medicinally for roughly two thousand years. In Ayurveda its root bark, Shyonaka, is one of the ten roots of Dashamoola, a formula described in classical texts such as the Charaka Samhita for inflammation, joint pain, fever, and respiratory complaints. Folk healers across India, Thailand, and Laos used the stem bark for diarrhea, jaundice, and wounds and ate the young pods and flowers, while traditional Chinese medicine uses the seeds (Mu Hu Die) for cough, hoarseness, and stomach pain (Dinda et al., 2015).

Modern interest began with plant chemistry: more than 100 compounds have been identified, and oroxylin A takes its name from the genus. From the 2000s, Korean groups reported that oroxylin A improved memory and attention-like behaviors in rodents (Kim et al., 2014; Yoon et al., 2013), while Chinese and Indian laboratories described anti-inflammatory, glucose-lowering, liver-protective, and anticancer effects.

Two paths from laboratory to people followed. Sabinsa, a supplement manufacturer, developed a bark extract standardized to oroxylin A, baicalein, and chrysin and funded the first human efficacy trial, published in 2021, in older adults with memory complaints (Lopresti et al., 2021). Chinese researchers separately advanced synthetic oroxylin A as a drug candidate for liver cancer and completed a first-in-human safety study (Yang et al., 2026).

The current standing reflects an early stage rather than a settled verdict: traditional use and laboratory findings are extensive, while controlled human outcome data rest on one trial not yet independently repeated.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the only human efficacy evidence is a single 12-week randomized trial, and every other finding comes from animal or cell studies.

Medium 🟩 🟩

Episodic Memory in Older Adults With Memory Complaints

In a 12-week randomized, placebo-controlled trial of 82 adults (mean age about 67) with self-reported memory decline, 500 mg of standardized bark extract twice daily improved episodic memory (recall of recent events and information), mainly word recall and numeric working memory, and sped location learning (Lopresti et al., 2021). Global cognition, self-rated cognition, most quality-of-life measures, and blood BDNF did not differ from placebo. The trial was co-authored by the manufacturer’s founder; rodent brain-aging studies support plausibility (Tanrangka et al., 2025).

Magnitude: Immediate word recall rose 5.4 percentage points versus a 1.0-point decline with placebo (Cohen’s d 0.52, a standardized effect size in which 0.5 is moderate); numeric working memory d 0.44; total Montreal Cognitive Assessment score unchanged.

Low 🟩

Modest Weight Reduction

In the same manufacturer-linked memory trial, weight fell more with the extract than with placebo, a secondary finding that narrowly missed statistical significance (Lopresti et al., 2021). Oroxylin A blocks fat-cell formation in cell studies (Singh & Kakkar, 2014). No weight-loss trial exists.

Magnitude: −1.1 kg versus −0.13 kg over 12 weeks (between-group p = 0.058, where p is the probability of a chance finding and 0.05 is the usual significance threshold).

Speculative 🟨

Attention and Impulse Control

Oroxylin A inhibits dopamine reuptake and reduced attention-deficit hyperactivity disorder-like behaviors in rats (Yoon et al., 2013). No controlled human study has measured attention; the basis is animal data and user anecdotes.

Blood Sugar Control

Oroxin A from the seeds slowed progression from prediabetes to diabetes in mice (Sun et al., 2018), and seed extract boosted the diabetes drug acarbose (Sun et al., 2017). The basis is animal data only.

Blood Lipids

Oroxin A lowered cholesterol and triglycerides in high-fat-fed rats via SREBP (sterol regulatory element-binding proteins, fat-synthesis switches) (Cai et al., 2024). No human lipid data exist; the basis is animal and cell work.

Liver Protection

Seed extract prevented fatty-liver inflammation in rats (Sun et al., 2021), and root-bark extract limited drug-induced liver damage in experimental models (Menon et al., 2026). Basis is preclinical only.

Digestive-Tract Protection

Root-bark extract reduced chemically induced colitis (colon inflammation) in rats (Joshi et al., 2011), and stem-bark flavonoids showed stomach-protective effects in rat ulcer models (Hari Babu et al., 2010). The basis is animal data only.

Cardiovascular and Anti-Clotting Protection

Oroxylin A reduced mouse arterial clotting (Chen et al., 2025); in Sabinsa-co-authored work, the extract limited chemotherapy heart damage (Pondugula et al., 2022). Basis is animal; human blood pressure was unchanged (Lopresti et al., 2021).

Cancer Prevention

Extracts slow cancer-cell growth and rodent tumors (Parvin et al., 2023); isolated oroxylin A is in early liver-cancer drug trials (a 2025 review by Luo et al.). No human outcome data exist; basis is preclinical.

Bone Preservation

Oroxylin A suppressed osteoclast (bone-resorbing cell) formation and bone resorption in laboratory studies (Xian et al., 2021). No human bone data exist; the basis is preclinical only.

Mood and Anxiety

Bark extract reduced anxiety- and depression-like behavior in mice (Aktaruzzaman et al., 2026). No controlled human mood outcome has been reported; the basis is animal data only.

Inflammation and Pain Relief

Stem-bark extract reduced paw swelling and pain responses in mice (Lalrinzuali et al., 2016), consistent with its traditional use for joint pain. No human study exists; the basis is animal data only.

Antimicrobial and Antiviral Activity

Extracts inhibited antibiotic-resistant hospital bacteria (Rattanasuk et al., 2025) and chikungunya virus (a mosquito-borne viral illness) (Mohamat et al., 2018) in laboratory assays. No human infection data exist; basis is laboratory only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No study has examined genotype. Variants in COMT (catechol-O-methyltransferase, an enzyme that breaks down dopamine) or the dopamine transporter gene plausibly shape response to a dopamine-reuptake inhibitor, but this is untested.
  • Baseline cognition: Benefits appeared in older adults with self-reported memory decline and near-normal screening scores; people with intact memory may have less room to improve, and people with diagnosed dementia were excluded.
  • Baseline biomarkers: Blood BDNF rose in both trial arms and did not track cognitive change (Lopresti et al., 2021). An ongoing trial enrolls people with insulin resistance (reduced response to insulin) (NCT07220694), testing whether metabolic dysfunction marks a responsive subgroup.
  • Sex: About three-quarters of trial participants were women, and sex differences were not analyzed (Lopresti et al., 2021); isolated baicalein reached higher blood exposure in women than men (Li et al., 2021), which may alter effective dose.
  • Pre-existing conditions: Prediabetes and fatty liver are where animal data are strongest, and attention-deficit disorders are a mechanistic target; evidence in all three groups is animal only.
  • Age: The only trial enrolled adults aged 60–85 (Lopresti et al., 2021), so midlife effects are unstudied; older adults may gain most for memory but carry more interaction risk from polypharmacy (use of multiple medications).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: human adverse-event data come from one 12-week trial of the bark extract and small phase I (first-in-human safety) trials of isolated oroxylin A and baicalein.

Medium 🟥 🟥

Digestive Upset and Headache

In the 12-week memory trial, adverse-event reports were more frequent with the extract (10 events) than placebo (6), mainly loose stools, nausea, bloating, and headache; one participant withdrew for persistent headaches, and none were serious (Lopresti et al., 2021). In a phase I study of isolated oroxylin A at 400–2,400 mg, gastrointestinal events were more frequent with repeated than single dosing (Yang et al., 2026). No serious adverse events occurred in either study.

Magnitude: 83% of extract users versus 87% of placebo users reported no adverse event over 12 weeks, a difference the authors described only as a tendency.

Low 🟥

Overstimulation and Sleep Disruption

One extract-group participant in the memory trial reported worsened sleep, versus none on placebo (Lopresti et al., 2021). Oroxylin A inhibits dopamine reuptake in cells (Yoon et al., 2013) and blocks a GABA-A receptor site in rodents (Huen et al., 2003). A single report cannot separate effect from chance.

Magnitude: 1 of 42 extract users versus 0 of 40 placebo users reported worsened sleep over 12 weeks.

Laboratory Changes in Triglycerides, Liver Enzymes, and Urine Protein

In a 10-day phase I trial of isolated baicalein, investigators judged raised triglycerides, urine protein, and liver-enzyme rises drug-related; all were mild and resolved (Li et al., 2021). Doses reached 1,800 mg daily, far above the 150 mg in the studied extract dose, so relevance is indirect.

Magnitude: 8 drug-related laboratory events in 30 baicalein recipients: raised triglycerides (3), urine protein (2), liver enzymes (2), and an inflammation marker (1); none required treatment.

Speculative 🟨

Increased Bleeding Tendency

Oroxylin A suppressed platelet activation and arterial clotting in mice, with less bleeding than aspirin (Chen et al., 2025). No human bleeding events are reported; basis is animal data only.

Altered Blood Levels of Medications

Baicalein inhibited CYP3A4 and tripled simvastatin exposure in rats (Meng et al., 2021); chrysin and baicalein also activate drug-metabolism signaling in human liver cells (Carazo Fernández et al., 2015). No human study exists.

Organ Toxicity and DNA Damage

Manufacturer-linked rodent studies found no organ or genetic toxicity (Majeed et al., 2025; Pondugula et al., 2021). A nitrite-treated fraction, unlike normal extracts, damaged rat stomach DNA (Tepsuwan et al., 1992). Basis is animal only.

Risk-Modifying Factors

  • Genetic polymorphisms: Weak UGT1A1 (the liver enzyme clearing bilirubin; weak in Gilbert syndrome, a benign bilirubin disorder) may slow flavone clearance; CYP3A5 (a drug-metabolizing liver enzyme) variants may alter interaction size. Both are untested.
  • Baseline biomarkers: Low platelet counts or prolonged clotting times magnify any antiplatelet (platelet-clumping-blocking) effect; low-normal fasting glucose raises theoretical hypoglycemia (low blood sugar) risk alongside glucose-lowering drugs.
  • Sex: Women reached higher baicalein blood exposure than men in a phase I study (Li et al., 2021), suggesting greater side-effect potential at equal doses; pregnancy and breastfeeding lack safety data.
  • Pre-existing conditions: Bleeding disorders, anxiety or insomnia, seizure disorders (theoretical, via GABA-A blockade), liver disease, and digestive sensitivity raise risk; trials excluded several of these groups.
  • Age: Adults over 70 more often take interacting anticoagulants (blood thinners), statins (cholesterol-lowering drugs), and sedatives and clear drugs more slowly; the trial’s upper age limit was 85 (Lopresti et al., 2021).

Key Interactions & Contraindications

Prescription drugs:

  • Drugs cleared by CYP3A4 (simvastatin, atorvastatin, tacrolimus, cyclosporine): Caution. Baicalein tripled simvastatin exposure in rats (Meng et al., 2021), raising muscle-injury and toxicity risk. Narrow-margin immunosuppressants (immune-dampening drugs) carry the greatest risk; for other drugs cleared this way, side-effect and drug-level monitoring detects this.
  • Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel): Caution. Oroxylin A’s antiplatelet activity may add to bleeding risk. For warfarin users, an INR (international normalized ratio, a clotting-time measure) check within 1–2 weeks of starting and attention to bruising are standard precautions.
  • Benzodiazepines (diazepam, alprazolam, lorazepam): Contraindicated when benzodiazepines control anxiety or panic; caution otherwise. Oroxylin A abolished diazepam’s anti-anxiety and muscle-relaxant effects, but not its anticonvulsant (anti-seizure) effect, in rodents (Huen et al., 2003), which could reduce therapeutic effect.
  • Stimulants and dopaminergic (dopamine-acting) drugs (methylphenidate, amphetamine, bupropion, selegiline): Caution. Additive dopamine-reuptake inhibition may increase restlessness, insomnia, heart rate, or blood pressure. Low starting doses and blood-pressure checks limit this.
  • Glucose-lowering drugs (metformin, glipizide, insulin, acarbose): Monitor. Seed extract enhanced acarbose in prediabetic mice (Sun et al., 2017); additive lowering could cause hypoglycemia. More frequent glucose checks during the first 4 weeks detect this.

Over-the-counter medications:

  • NSAIDs (nonsteroidal anti-inflammatory drugs: ibuprofen, naproxen, aspirin): Caution. Additive platelet inhibition and stomach irritation increase bleeding and digestive risk. Limiting regular combined use and dosing the extract with food reduce this.
  • Caffeine: Monitor. Chrysin inhibited caffeine-clearing liver enzymes in rat liver tissue but left caffeine blood levels unchanged in rats (Noh et al., 2016); stimulant effects may still add up. Less caffeine eases restlessness or insomnia if these appear.

Supplements:

  • Dopaminergic nootropics (cognitive-enhancing supplements such as L-Tyrosine, Mucuna pruriens, phenylethylamine): Caution. Additive stimulation may cause restlessness, insomnia, or raised blood pressure. Introducing one agent at a time shows which one causes effects.
  • Scutellaria baicalensis (Chinese skullcap): Monitor. Contains the same flavones (baicalein, oroxylin A), raising total dose and the risk of digestive upset and drug interactions. Tallying combined flavone intake limits this.
  • Antiplatelet supplements (fish oil, Ginkgo biloba, high-dose vitamin E, garlic): Caution. Additive bleeding tendency. A 2-week pause before surgery limits this.
  • Glucose-lowering supplements (berberine, cinnamon, chromium): Monitor. Additive glucose lowering may cause hypoglycemia with diabetes drugs. Fasting glucose checks detect this.
  • Piperine (black pepper extract): Monitor. Used in an ongoing trial to raise flavone absorption (NCT07220694); it also inhibits CYP3A4 and P-glycoprotein (a drug-efflux pump), potentially raising levels of co-administered drugs. Piperine-free products limit this.

Other interventions:

  • Surgery and dental procedures: Caution. Theoretical bleeding risk from antiplatelet flavones. Stopping 1–2 weeks before scheduled procedures reduces this.

Populations who should avoid Oroxylum indicum:

  • Pregnant or breastfeeding women (no human safety data)
  • Children and adolescents under 18 (untested)
  • People with bleeding disorders, platelet counts below 100,000/µL, or surgery within 2 weeks
  • People taking tacrolimus, cyclosporine, or other narrow-margin CYP3A4 drugs, or warfarin without INR monitoring
  • People whose anxiety or panic disorder is controlled with benzodiazepines
  • People with decompensated liver disease (Child-Pugh Class B or C, a liver-disease severity score)
  • People with uncontrolled anxiety, insomnia, or bipolar disorder

Risk Mitigation Strategies

  • Dosing with meals: Dosing after breakfast and lunch reduces the nausea, loose stools, and bloating seen in the trial; food also raised isolated oroxylin A absorption (Yang et al., 2026), so consistent timing steadies exposure.
  • Low start, gradual increase: Beginning at 250 mg daily for 1 week, then 500 mg daily, and reaching 500 mg twice daily after 2 weeks limits digestive upset, headache, and overstimulation.
  • Earlier dosing when sleep suffers: Moving the second dose to early afternoon (before 2 p.m.) limits sleep disruption from dopaminergic activity.
  • Medication review before starting: Screening for CYP3A4-dependent drugs, anticoagulants, benzodiazepines, and stimulants prevents unrecognized interactions; pharmacist review is common practice for anyone taking 3 or more prescriptions.
  • Pre-procedure pause: Stopping 14 days before surgery or dental extraction reduces the theoretical bleeding risk from antiplatelet flavones.
  • Liver and blood-count checks: ALT (alanine aminotransferase, a liver-injury marker) and a complete blood count at baseline, 4, and 12 weeks detect rare herbal liver injury or platelet effects; stopping if ALT exceeds 3 times normal.
  • Glucose monitoring with diabetes drugs: Fasting glucose checks 2–3 times weekly for the first 4 weeks prevent hypoglycemia when combined with glucose-lowering medications.
  • Third-party-tested standardized extract: Products standardized to oroxylin A with contaminant testing reduce the risk of adulterated bark, heavy metals, or mislabeled species.

Therapeutic Protocol

  • Clinical-trial protocol: 500 mg standardized bark extract (Sabroxy: 10% oroxylin A, 6% chrysin, 15% baicalein) orally twice daily, morning and evening, for 12 weeks; developed by Sabinsa and the only regimen tested against placebo (Lopresti et al., 2021).
  • Lower-dose nootropic approach: 100–250 mg once daily in the morning, popularized by nootropic retailers such as Nootropics Depot for focus; an ongoing trial pairs 250 mg with 5 mg piperine (NCT07220694). Efficacy at these doses is unmeasured.
  • Traditional Ayurvedic approach: Root bark within boiled Dashamoola preparations or fermented Dashamoolarishta, used by Ayurvedic practitioners following the classical texts; not standardized for flavones and not tested for longevity outcomes.
  • Traditional Chinese approach: Seeds (Mu Hu Die) at 1–3 g daily, boiled in water, for cough and sore throat, following Chinese pharmacopeia practice; not a longevity protocol.
  • Time of day: Morning and early-afternoon dosing fits the alerting dopaminergic profile; the trial allowed dosing with or without food (Lopresti et al., 2021), but post-meal dosing improves digestive tolerance.
  • Half-life: Isolated baicalein has a terminal half-life of about 11–15 hours in humans (Li et al., 2021); chrysin and oroxylin A are rapidly conjugated, and oroxylin A data support once-daily dosing (Yang et al., 2026). Whole-extract half-life is unmeasured.
  • Single vs. split dosing: The trial used twice-daily dosing (Lopresti et al., 2021), which smooths exposure given rapid conjugation; a single morning dose reduces sleep interference but is untested for memory outcomes.
  • Genetic considerations: No data link gene variants to dosing; people with Gilbert syndrome (reduced UGT1A1 activity) may accumulate flavone conjugates, making the lower end of the dose range a conservative option.
  • Sex-based differences: Women showed higher baicalein exposure than men in a phase I study (Li et al., 2021); no sex-specific dosing exists, and a lower starting dose in smaller women is one conservative option.
  • Age considerations: Trial participants were 60–85 (Lopresti et al., 2021); for older adults with slower clearance and more medications, a 250–500 mg daily start is a conservative entry point.
  • Baseline biomarkers: Baseline memory testing and fasting glucose frame response; the trial effect appeared in people with self-reported decline and near-normal global screening scores (Lopresti et al., 2021).
  • Pre-existing conditions: Mild memory complaints, insulin resistance (under study), and attention problems are the target groups; liver disease and bleeding disorders fall outside tested populations.

Discontinuation & Cycling

  • Short-term vs. lifelong: Evidence covers 12 weeks only; longer use is untested, so use is framed as a defined trial period with reassessment rather than lifelong intake.
  • Withdrawal effects: None were reported after the 12-week trial (Lopresti et al., 2021), and no dependence has been described; users occasionally report transiently reduced focus after stopping high doses (anecdotal).
  • Tapering: Not required based on available data; a 1-week step-down is optional for people who experienced strong stimulant-like effects.
  • Cycling: No evidence shows that cycling preserves efficacy. Some nootropic users take 5 days on and 2 days off to limit possible tolerance to dopaminergic effects; this practice is untested.
  • Reassessment point: Repeating memory testing at 12 weeks gives an objective basis for continuing or stopping.

Sourcing and Quality

  • Plant part matters: Stem bark (standardized extract, folk use), root bark (Ayurvedic Shyonaka), and seeds (Chinese Mu Hu Die, rich in oroxin glycosides) differ in flavone profiles, so results from one part do not transfer automatically.
  • Standardization: The only clinically tested extract is standardized to 10% oroxylin A, 6% chrysin, and 15% baicalein; unstandardized bark powders have unknown and variable flavone content.
  • Third-party testing: Certificates of analysis covering flavone content, heavy metals, and microbial contamination, or USP (United States Pharmacopeia) or NSF International certification, reduce quality risk.
  • Adulteration and substitution: Traded bark and root are subject to adulteration, and herbal-medicine quality reviews call for better quality-control methods (Anmol et al., 2024).
  • Reputable sources: Sabinsa supplies Sabroxy to brands such as Nootropics Depot; established Ayurvedic manufacturers (Dabur, Baidyanath) sell Dashamoolarishta. Brand mention is not an endorsement.
  • Sustainability: The species is described as endangered in parts of its range because of root and bark harvesting; cultivated sources reduce pressure on wild populations.

Practical Considerations

  • Time to effect: Memory differences were measured at 12 weeks (Lopresti et al., 2021); earlier time points were not tested for cognition. Users report acute alertness within hours, but this is anecdotal.
  • Common pitfalls: Confusing Oroxylum indicum with Scutellaria baicalensis products that share its flavones, buying unstandardized powders, dosing late in the day, and expecting stimulant-like effects from an extract whose trial showed modest memory gains.
  • Regulatory status: Sold as a dietary supplement ingredient in the United States and not approved by the FDA (Food and Drug Administration) for any condition; an Ayurvedic medicine in India; isolated oroxylin A is an investigational drug in China.
  • Cost and access: Standardized extracts are widely available online and are not exceptionally expensive.
  • Research independence: The human efficacy trial and much of the safety work come from Sabinsa, the extract’s manufacturer, or its co-authors; no independent replication exists.

Interaction with Foundational Habits

  • Sleep: Potentially blunting. Oroxylin A’s dopamine-reuptake inhibition and GABA-A antagonism are alerting in rodents, and one extract-group trial participant reported worsened sleep (Lopresti et al., 2021). Morning dosing and no doses after early afternoon limit interference; tracking time to fall asleep and wearable sleep scores detects problems.
  • Nutrition: Direct and potentiating. Food increased isolated oroxylin A absorption (Yang et al., 2026), so dosing with meals improves tolerability and exposure. Animal data suggest additive glucose and lipid benefits alongside lower-sugar, lower-saturated-fat diets; young pods and flowers are eaten as vegetables in Thailand and Northeast India.
  • Exercise: Indirect; no human data. Whether its antioxidant actions blunt training adaptations, as reported for high-dose vitamins C and E (Paulsen et al., 2014), is untested. Morning dosing before training may sharpen focus, based only on user anecdotes.
  • Stress management: Direct, with blunting and potentiating signals. GABA-A antagonism could weaken the calming effect of benzodiazepines and may heighten arousal in anxious people, whereas bark extract reduced anxiety-like behavior in mice (Aktaruzzaman et al., 2026). Breathing practices, meditation, and sleep hygiene remain the main tools; anxiety ratings detect adverse arousal.

Monitoring Protocol & Defining Success

Baseline testing: Before starting, a baseline panel captures liver enzymes, a complete blood count, and glucose markers, plus an objective cognitive score, so that side effects and benefits can be judged against the individual’s own starting point. People taking warfarin add an INR; those with insulin resistance add fasting insulin.

Ongoing monitoring: Liver enzymes and blood counts are repeated at 4 weeks and 12 weeks, then every 6–12 months with continued use. Cognitive testing is repeated at 12 weeks, matching the trial duration, and every 6 months thereafter. Glucose checks follow the same cadence, more often when glucose-lowering drugs are used. A meaningful response is a sustained improvement in recall or working-memory scores beyond normal test–retest variation, without new adverse effects.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT 10–25 U/L Liver injury Conventional upper limit about 40–55 U/L; above 3 times the upper limit is the usual stopping threshold; paired with AST (aspartate aminotransferase)
AST 10–25 U/L Liver or muscle injury Conventional upper limit about 40 U/L
Platelet count (complete blood count) 200,000–300,000/µL Bleeding-risk baseline Conventional range 150,000–400,000/µL
Fasting glucose 75–90 mg/dL Metabolic effect; hypoglycemia risk Conventional normal below 100 mg/dL; 8–12 hour fast, morning draw
HbA1c 4.8–5.3% 3-month glucose average HbA1c: hemoglobin A1c; conventional normal below 5.7%
Fasting insulin 2–6 µIU/mL Insulin sensitivity Conventional upper limit up to about 25 µIU/mL; pair with fasting glucose to calculate HOMA-IR (homeostatic model assessment of insulin resistance)
INR (if on warfarin) Individual therapeutic target, usually 2.0–3.0 Detects interaction Usually checked 1–2 weeks after starting or changing dose
hs-CRP Below 1.0 mg/L Systemic inflammation hs-CRP: high-sensitivity C-reactive protein; conventional cutoff below 3.0 mg/L; acute illness distorts results
Serum BDNF No established target; track change from own baseline Research marker of nerve-cell support Did not differ from placebo in the trial; varies by season and exercise; fasting morning draw
Montreal Cognitive Assessment 26–30 of 30; track change from own baseline Global cognition Not a lab test; pair with computerized word-recall and working-memory tasks

Qualitative markers:

  • Everyday memory (misplaced items, forgotten names, lost train of thought)
  • Focus and mental energy during demanding tasks
  • Sleep quality and time to fall asleep
  • Digestive comfort
  • Headache frequency
  • Mood and anxiety levels

Emerging Research

  • Extract for insulin resistance and cognition (NCT07220694): Randomized, placebo-controlled 8-week trial of 250 mg extract plus 5 mg piperine in 140 adults aged 40–80 with insulin resistance and mild cognitive impairment; primary endpoint HOMA-IR. Sponsored with Sabinsa; recruiting. Could extend the case to metabolic health.
  • Unpublished US memory trial (NCT07189754): Randomized, placebo-controlled trial completed in 2021 in 70 adults aged 60–85 with memory concerns; registered retrospectively in 2025 with no posted results. Publication could confirm or weaken the Australian findings (Lopresti et al., 2021).
  • Oroxylin A as a drug: A first-in-human study found single doses up to 2,400 mg of isolated oroxylin A free of dose-limiting toxicity (Yang et al., 2026); oroxylin A tablets are in early-phase (phase Ib/IIa) liver-cancer trials registered in China rather than on ClinicalTrials.gov (a 2025 review by Luo et al.).
  • Comparative efficacy: A network meta-analysis of 18 botanicals for mild cognitive impairment included the extract but ranked Pycnogenol highest for cognition (Yang et al., 2025), tempering expectations while only one trial exists.
  • Absorption as the key unknown: Human data show very low free-flavone exposure after oral dosing (Walle et al., 2001); studies measuring brain-relevant exposure, or piperine-enhanced formulations, could either strengthen or undermine the mechanistic case.
  • Metabolic translation: Animal findings on prediabetes (Sun et al., 2018) and fatty liver (Sun et al., 2021) await human testing; the insulin-resistance trial above is the first direct test.

Conclusion

Oroxylum indicum is an Asian medicinal tree whose bark supplies a group of plant compounds that, in laboratory studies, calm inflammation, support nerve cells, and slow the clearance of dopamine, a brain messenger tied to focus. For health-focused adults, its appeal centers on memory, with secondary interest in blood sugar, liver fat, and heart protection.

The human evidence is thin. A single placebo-controlled trial in older adults with memory complaints found better performance on some memory tasks, but not on overall thinking scores or self-rated memory. That trial, much of the safety testing, and several animal studies were co-authored or funded by the company that sells the standardized extract, and no independent group has yet repeated the findings. Benefits for blood sugar, cholesterol, liver health, bone, and cancer rest on animal and cell research alone, and the body absorbs only small amounts of the active compounds.

Reported side effects are mild and mostly digestive, along with headache. The more meaningful considerations for this audience are possible interactions with drugs cleared by the liver, with blood thinners, with anti-anxiety sedatives, and with stimulants, as well as possible sleep disruption when taken late in the day.

Overall, the herb sits at an early stage: a long traditional record, a plausible biology, reassuring short-term safety, and one encouraging but manufacturer-linked memory result, leaving its value for long-term healthy aging uncertain.

Top - Benefits - Risks - Protocol